Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AK139 in Healthy Subjects
NCT06947109Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis (AD) comparing AK139 with Placebo (2 arms). Primary endpoint: Adverse Events (AE). Planned start May 2025; status: not yet recruiting.
02
Drugs
AK139
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06947109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947109.